36P - Gene expression analysis of triple negative recurrent lymphangitic breast cancer in patients receiving antiangiogenic therapy

Date 08 May 2014
Event IMPAKT 2014
Session Welcome reception and Poster Walk
Topics Breast Cancer
Translational Research
Presenter Lucia Gelao
Citation Annals of Oncology (2014) 25 (suppl_1): i8-i16. 10.1093/annonc/mdu066
Authors L. Gelao1, V. Bagnardi2, M.A. Locatelli1, F. Bertolini3, C. Criscitiello1, A. Esposito1, G. Viale4, M. Alkalay5, A. Goldhirsch6, G. Curigliano1
  • 1Early Drug Development For Innovative Therapy Division, European Institute of Oncology, 20141 - Milan/IT
  • 2Division Of Epidemiology And Biostatistics, Department Of Statistics And Quantitative Methods, University Of Milan-bicocca, Istituto Europeo di Oncologia, 20141 - Milano/IT
  • 3Laboratory Division Of Haemato-oncology, European Institute of Oncology, 20141 - Milan/IT
  • 4Division Of Pathology, University Of Milan, School Of Medicine, Istituto Europeo di Oncologia, 20141 - Milano/IT
  • 5University Of Milan, University of Milan, 20141 - Milano/IT
  • 6Oncologia Medica 1, Istituto Europeo di Oncologia, 20141 - Milano/IT

Abstract

Purpose:

To identify a gene signature predictive of response to treatment with bevacizumab. To assess efficacy and safety of bevacizumab in combination with oral chemotherapy in patients with inflammatory breast cancer.

Patients and methods:

We randomly assigned patients to receive oral vinorelbine 55 mg/m2 on days 1 and 3 and capecitabine 2000 mg/m2 from day 1 to 14 every 3 weeks either concurrent or sequential to bevacizumab 15 mg per kilogram of body weight on days 1 and 21. The primary end point was progression-free survival; the response rate and overall survival were secondary end points. We performed gene expression profiling on collected baseline tissue samples using Affymetrix HG-U133 Plus 2.0 arrays.

Results:

From July 2007 through October 2011, a total of 66 patients were enrolled. Concurrent oral vinorelbine and capecitabine plus bevacizumab significantly increased the objective response rate as compared to the sequential treatment (11.1% vs. 46.4%, P < 0.001). No difference in progression-free survival was observed between the two arms (median time to progression 4.3 vs. 4.7 months, p = 0.69; Hazard Ratio: 0.86, 95% CI: 0.41–1.80). Global gene expression was analyzed in tumor samples from patients bearing a triple negative phenotype. A set of 75 genes was identified, this gene signature correlates with response to bevacizumab.

Conclusions:

Oral vinorelbine plus capecitabine and bevacizumab (BEVIX) is an active treatment for patients with recurrent lymphangitic breast cancer. We identified a set of 75 genes whose expression levels predict the response to BEVIX.

Disclosure:

All authors have declared no conflicts of interest.